• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Collaborative home-based palliative care approach effective for heart failure patients

byDavy LauandAlex Chan
October 12, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
Share on FacebookShare on Twitter

1. A regional collaborative, home-based palliative care (CHPC) program for heart failure (HF) patients was associated with 48% decrease in in-hospital death, with a number needed to treat of 3.

2. The CHPC program was also associated with shorter hospital stays, increased time to first hospital admission, and decreased rates of hospital admission, ED use, and ICU use.

Evidence Rating Level: 2 (Good)

Study Rundown: At-home death and avoiding unwanted hospital treatments are both indicators of quality palliative care. However, a study in Ontario, Canada found that 75% of patients with heart failure (HF) passed away in hospital between 2010 and 2015, and 32% received home-based palliative care, despite other studies showing that as much as 90% of individuals prefer end-of-life care to happen at home. Currently, the literature on collaborative home-based palliative care (CHPC) models for HF patients have been single centre and not included an approach with in-person home visits, and they’ve shown mixed results on quality of life indicators. Therefore, this current matched cohort study based out of Ontario, Canada aimed to implement a CHPC program for HF patients, with the primary outcome measured being rates of death out-of-hospital. CHPC patients were matched to usual-care patients by their duration of disease, date of passing, and likelihood of receiving palliative care, but was not able to account for NYHA class or LVEF, as that data was unavailable for the non-CHPC patients. Overall, the study demonstrated a 48% decreased risk of passing away in hospital with the CHPC patients, as well as shorter hospital stays, increased time to first hospital admission, and decreased rates of hospital admission, use of the emergency department (ED), use of intensive care (ICU).

Click here to read the study in CMAJ

Relevant Reading: Association between palliative care and healthcare outcomes among adults with terminal non-cancer illness: population based matched cohort study

RELATED REPORTS

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

Chronic exposure to particulate matter is associated with increased cardiovascular risk

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

In-depth [retrospective cohort study]: The study population consisted of 245 HF patients who received CHPC matched to 1172 who received care as usual, who passed away between 2013 and 2019. To get into a CHPC program, patients are referred by their primary care or specialist providers. The core principles emphasized in CHPC are: collaboration amongst healthcare providers (cardiologists, primary care, and palliative care), shared decision making, advanced care planning, and education on managing HF at home. This would involve an initial visit with a palliative care provider to assess goals of care and decision-making needs, provide supplies, and offer contact information to reach a palliative provider 24/7. The palliative team would then pass on the care plan to the patient’s other healthcare providers. Overall, the results showed that 41.2% of CHPC patients passed away in hospital, compared to 78.2% of usual care patients, representing a 48% decreased risk of dying in hospital for the CHPC patients (relative risk 0.52, 95% CI 0.44-0.61) with a number needed to treat of 3. Additionally, the study found that CHPC was associated with increased time to first hospital admission (hazard ratio 0.39, 95% CI 0.31-0.5), and lower rates of hospital admission (RR 0.64, 95% CI 0.55-0.74), ED use (RR 0.67, 95% CI 0.55-0.82), and ICU use (RR 0.57, 95% CI 0.39-0.84).  In conclusion, a regional CHPC model was implemented that improved numerous outcomes, such as out-of-hospital death, amongst other indicators of quality end-of-life care.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologyheart failurepalliative care
Previous Post

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Next Post

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

RelatedReports

Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

A medical care at home program following hospitalization with acute decompensated heart failure may offer a safe and effective alternative to continued hospitalization

July 24, 2026
Next Post
Adding sargramostim to ipilimumab may improve survival in advanced melanoma

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

#VisualAbstract: Cefepime/enmetazobactam superior to piperacillin/tazobactam for the treatment of complicated urinary tract infections and acute pyelonephritis

#VisualAbstract: Cefepime/enmetazobactam superior to piperacillin/tazobactam for the treatment of complicated urinary tract infections and acute pyelonephritis

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.